title: Translational PK-PD modeling in pain.
abstract: The current gap between animal research and clinical development of analgesic drugs presents a challenge for the application of translational PK-PD modeling and simulation. First, animal pain models lack predictive and construct validity to accurately reflect human pain etiologies and, secondly, clinical pain is a multidimensional sensory experience that can't always be captured by objective and robust measures. These challenges complicate the use of translational PK-PD modeling to project PK-PD data generated in preclinical species to a plausible range of clinical doses. To date only a few drug targets identified in animal studies have shown to be successful in the clinic. PK-PD modeling of biomarkers collected during the early phase of clinical development can bridge animal and clinical pain research. For drugs with novel mechanism of actions understanding of the target pharmacology is essential in order to increase the success of clinical development. There is a specific interest in the application of human pain models that can mimic different aspects of acute/chronic pain symptoms and serves as link between animal and clinical pain research. In early clinical development the main objective of PK-PD modeling is to characterize the relationship between target site binding and downstream biomarkers that have a potential link to the clinical endpoint (e.g. readouts from the human pain models) so as to facilitate the selection of doses for proof of concept studies. In patient studies, the role of PK-PD modeling and simulation is to characterize and confirm patient populations in terms of responder profiles with the aim to find the right dose for the right patient.
authors.affiliation: Global Clinical Pharmacology and Exploratory Development, Astellas Pharma Global Development Europe, Elisabethhof 1, PO BOX 108, 2350 AC, Leiderdorp, The Netherlands. ashraf.yassen@astellas.com
authors.forename: Ashraf
authors.initials: A
authors.lastname: Yassen
authors.forename: Paul
authors.initials: P
authors.lastname: Passier
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Furuichi
authors.forename: Albert
authors.initials: A
authors.lastname: Dahan
mesh_terms: D000700:Analgesics / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D003198:Computer Simulation; D006801:Humans; D008954:Models, Biological; D010146:Pain / Q000097:blood / Q000188:drug therapy*; D014018:Tissue Distribution; D016896:Treatment Outcome
chemical_list: D000700:Analgesics; D000701:Analgesics, Opioid